fujikura exercises its option to license cellm, page-8

Another box ticked again by CDY and this just another door that opens for CDY in the diagnostic space to grow this company into a major worldwide player with a multifaceted business model. All is coming together and a global approach is coming together with Asia being the major focus so far on both diagnostic and evolis fronts. I would expect a move on Europe and the US to really take this company forward over the second half year and into 2014. The team at CDY is growing this business and adding significant value to shareholders and the market for biotech's has been heating up as the mining sector looks to have run out of steam. CDY should be coming up on a number of alerts in the investment community with the growing business they are achieving and not to forget the influence that Martin Rogers is having on the biotech's he is involved with. The trend is heading back in the right direction.